APLS
Apellis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$41.03
+0.00%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- 38.71x
- PEG TTM
- —
- Price / book
- 12.66x
- Price / sales
- 4.75x
- Price / cash flow
- 139.07x
Enterprise value
- Enterprise value
- $5.3B
- EV / sales
- 4.81x
- EV / EBITDA
- 30.04x
- EV / EBIT
- 32.21x
- Market cap
- $5.3B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026